0 41

Cited 0 times in

Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma

Authors
 Ga-Young Song  ;  Dok Hyun Yoon  ;  Cheolwon Suh  ;  Joon Ho Moon  ;  Dong Won Baek  ;  Jin Seok Kim  ;  Gyeong-Won Lee  ;  Jun Ho Yi  ;  Yong Park  ;  Ki Sun Jung  ;  Seok Jin Kim  ;  Deok-Hwan Yang  ;  Won Seog Kim 
Citation
 BONE MARROW TRANSPLANTATION, Vol.56(5) : 1205-1208, 2021-05 
Journal Title
BONE MARROW TRANSPLANTATION
ISSN
 0268-3369 
Issue Date
2021-05
MeSH
Antineoplastic Combined Chemotherapy Protocols / therapeutic use ; Combined Modality Therapy ; Hematopoietic Stem Cell Transplantation* ; Humans ; Induction Chemotherapy ; Lymphoma, Extranodal NK-T-Cell* / therapy ; Neoplasm Recurrence, Local ; Stem Cell Transplantation ; Transplantation, Autologous
Abstract
The clinical outcome of advanced-stage Extranodal NK/T cell lymphoma (ENKTL) patients using conventional chemotherapy is extremely poor. The aim of this study was to investigate the outcomes of advanced-stage ENKTL patients treated with non-anthracycline-based chemotherapy followed by upfront autologous stem cell transplant (ASCT). From 8 institutions, 27 patients were recruited from February 2016 to May 2019. Patients were treated with 4 cycles of VIDL induction chemotherapy. Patients who achieved complete response (CR) or partial response (PR) underwent upfront ASCT. This study is registered with clinicaltrial.gov, # NCT02544425. Twenty patients (74.1%) completed 4 cycles of VIDL induction. The overall response rate of VIDL was 74.1%, including 17 (63.0%) with CR and 3 (11.1%) with PR. Primary toxicity of the induction regimen was grade 3 or 4 neutropenia, and no treatment-related mortality was reported. Seventeen patients proceeded with upfront ASCT, and 9 patients relapsed after ASCT, among whom, 4 was central nervous system (CNS) relapse. The median duration of response was 15.2 months (95% CI, 6.3-24.1 months). This study suggested that VIDL induction chemotherapy followed by upfront ASCT is feasible and effective for the treatment of advanced-stage ENKTL. However, CNS relapse prevention is needed in the treatment of advanced-stage ENKTL.
DOI
10.1038/s41409-020-01160-2
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190919
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links